Skip to content
dough· @semodough · X·· 2026-04-19Score60
Body

$IDYA #AACR26 IDYA: multiple preclinical data for IDE892 (PRMT5i), IDE034 (B7H3/PTK7 ADC), and IDE574 (KAT6/7i), as well as potential readthrough to IDE849 (DLL ADC) from $ZLAB's zoci in ES-SCLC with CNS mets, neuroendocrine carcinomas, and other tumors.

Heat 8 · 7 likes · 0 replies · 1 repost

Conference abstracts
4483matched by 代号 IDE574
The KAT6/7 inhibitor IDE574 disrupts tumor lineage identity and drug tolerance to deliver robust antitumor activity in biomarker selected indications.

Manav Gupta, Scott R. Tyler, Nour Ghaddar, Carl Schultz, Pranav Gupta, Steven L. Spivak, Katelyn N. Lukas, Zabrisky Roland, Anjali Bisaria, Mona Khalaj, Mason Appel, Oscar Aubi, Kelly S. Trego, Parker Y. Jameson, Jacob Burch-Konda, Angelica Gonzalez-Sanchez, Brittany Cruzan, Rushika Pandya, Jay Prakash Jain, Michael E. Dalziel, Julie Deichert, Sunjay Sethi, Ivan G. Shabalin, Jonathon S. Ryan, Daniel M. Walden, Muzaffar Alam, Daniel Severance, Amber C. Donahue, Edward Chan, Rebeca Choy, Diana M. Muñoz, Richard Zang, Xin Linghu, Peter Teriete, Christian R. Frey, Yuchen Bai, Claire L. Neilan, Josh Taygerly, Paul A. Barsanti, Michael A. White, Brian T. Jones

Read the abstract →
4505matched by 代号 IDE892
IDE892 is a highly potent and selective PRMT5 inhibitor, with MTA-positive and SAM-negative cooperativity, optimized for development in MTAPdel cancers in combination with the allosteric MAT2A inhibitor IDE397.

Arjun A. Rao, Marcus M. Fischer, Rebeca M. Choy, Angelica M. Gonzalez-Sanchez, Natalie Bresnahan, Zhipeng Fang, Mason J. Appel, Atul Rathore, Oscar Aubi, Shannon Faris, Parker Y. Jameson, Zabrisky Roland, David Trinh, Kelly Trego, John Vivian, Michael E. Dalziel, Christian R. Frey, Yuchen Bai, Jasgit Sachdev, Claire L. Neilan, Jay Prakash Jain, Michael A. White, Paul A. Barsanti, Peter Teriete, Melissa Fleury

Read the abstract →

Source: dough · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org